Cover Image

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension

The TOMORROW trial of nintedanib comprised a randomised, placebo-controlled, 52-week period followed by a further blinded treatment period and an open-label extension. We assessed outcomes across these periods in patients randomised to nintedanib 150 mg twice daily or placebo at the start of TOMORRO...

Full description

Saved in:
Bibliographic Details
Main Authors: Richeldi, Luca (Author) , Kreuter, Michael (Author) , Quaresma, Manuel (Author)
Format: Article (Journal) Editorial
Language:English
Published: 2018
In: Thorax
Year: 2018, Volume: 73, Issue: 6, Pages: 581-583
ISSN:1468-3296
DOI:10.1136/thoraxjnl-2016-209701
Online Access:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1136/thoraxjnl-2016-209701
Verlag, kostenfrei, Volltext: http://thorax.bmj.com/content/73/6/581
Get full text
Author Notes:Luca Richeldi, Michael Kreuter, Moisés Selman, Bruno Crestani, Anne-Marie Kirsten, Wim A. Wuyts, Zuojun Xu, Katell Bernois, Susanne Stowasser, Manuel Quaresma, Ulrich Costabel
Description
Summary:The TOMORROW trial of nintedanib comprised a randomised, placebo-controlled, 52-week period followed by a further blinded treatment period and an open-label extension. We assessed outcomes across these periods in patients randomised to nintedanib 150 mg twice daily or placebo at the start of TOMORROW. The annual rate of decline in FVC was −125.4 mL/year (95% CI −168.1 to −82.7) in the nintedanib group and −189.7 mL/year (95% CI −229.8 to −149.6) in the comparator group. The adverse event profile of nintedanib remained consistent throughout the studies. These results support a benefit of nintedanib on slowing progression of idiopathic pulmonary fibrosis beyond 52 weeks.
Item Description:Published Online First 9 October 2017
Gesehen am 29.05.2018
Physical Description:Online Resource
ISSN:1468-3296
DOI:10.1136/thoraxjnl-2016-209701

Similar Items